Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 20 of 25, showing 5 Applications out of 123 total, starting on record 96, ending on 100

# Protocol No Study Title Investigator(s) & Site(s)

96.

ECCT/16/05/03   Clinical trial of neem & coconut oils for tungiasis
    Phase IIA, randomised controlled trial of a locally-made, herbal remedy (neem & coconut oil) for treatment of jiggers (Tunga penetrans)   
Principal Investigator(s)
1. Ulrike Fillinger
Site(s) in Kenya
Dabaso Tujengane CBO
 
View

97.

ECCT/16/05/01   A5338
    A5338   An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among   Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz   (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and   Tuberculosis (TB)   
Principal Investigator(s)
1. David Schnabel
Site(s) in Kenya
KISUMU CRS
 
View

98.

ECCT/16/04/01   HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection
    HVTN 703/HPTN 081   A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection   
Principal Investigator(s)
1. Dr. Victor Akelo Akelo
Site(s) in Kenya
KISUMU CRS
 
View

99.

ECCT/16/03/02   Infant TB Infection Prevention Study (“iTIPS”)
    Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants       
Principal Investigator(s)
1. Grace John-Stewart
Site(s) in Kenya
1. Kisumu East District Hospital (Kisumu county)
2. Ahero County Hospital (Kisumu county)
3. Bondo sub-County Hospital (Kisumu county)
 
View

100.

ECCT/16/02/06   A study of the safety and immune response of 2 doses of a new Shigella vaccine in Kenyan adults.
    A Phase 2a, observer blind, randomized, controlled, Single Center Study to evaluate the Safety, Reactogenicity and Immunogenicity of 2 doses of the GVGH 1790GAHB Vaccine against Shigella sonnei, administered intramuscularly in Adult Subjects from a country endemic for shigellosis [GVGH study H03_04TP]   
Principal Investigator(s)
1. Christina Wesonga Obiero
Site(s) in Kenya
Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme
 
View